CadheRx Therapeutics' Series A Round

CadheRx Therapeutics raised a round of funding on June 15, 2015.

CadheRx is developing therapeutic antibodies targeting soluble E-cadherin (sEcad) for the treatment of solid tumors that are resistant to other treatments, particularly Cetuximab and Herceptin resista…

Articles about CadheRx Therapeutics' Series A Round: